See Editas Medicine's analyst price targets ($4) vs the current share price.
Get informed when a big investor buys or sells
+ Follow$2.68
1 analysts in the last 4 months
High: $4 | Low: $4
No recommendations in the last 4 months.
The latest target price for EDIT is $4. Investors often review this figure alongside Editas Medicine's historical trend and sector peers before judging valuation or financial health.
Editas Medicine trades near $2.68 while the consensus target sits at $4 (49.3% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.
After noting EDIT's target price ($4), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Editas Medicine's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.